Wockhardt Exits US Generics Biz To Focus On Antibiotics, Insulin Portfolio

Wockhardt Ltd. on Friday said it is exiting the generic pharmaceuticals business in the US with immediate effect, to prioritise its new antibiotic drug discovery pipeline and biologicals portfolio in insulin.

The company said the US generics segment, which contributes less than 5% to overall sales, incurred a loss of nearly $8 million in 2024-25. “Continuing in this segment would detract from its broader innovation agenda,” the company said following a strategic review.

Wockhardt has filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its step-down units Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC, both incorporated in Delaware. The subsidiaries are fully owned by Wockhardt Bio AG.

The company said the exit will free up capital and management bandwidth to scale up its innovation-led focus areas, including differentiated antibiotics and biologics for diabetic care. It also reaffirmed its commitment to India, the UK, Ireland, and other markets where performance remains strong.